Business Description
Summit Therapeutics Inc
NAICS : 541714
SIC : 2833
Share Class Description:
MEX:SMMT: Ordinary SharesDescription
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 14.98 | |||||
| Equity-to-Asset | 0.87 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.18 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -9.7 | |||||
| 3-Year EPS without NRI Growth Rate | 41.3 | |||||
| 3-Year FCF Growth Rate | 43.8 | |||||
| 3-Year Book Growth Rate | -51.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 99.33 | |||||
| 9-Day RSI | 85.21 | |||||
| 14-Day RSI | 54.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.31 | |||||
| Quick Ratio | 8.31 | |||||
| Cash Ratio | 8.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -104.1 | |||||
| Shareholder Yield % | 0.88 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -115.11 | |||||
| ROA % | -68.15 | |||||
| ROIC % | -268.04 | |||||
| ROC (Joel Greenblatt) % | -2347.31 | |||||
| ROCE % | -85.21 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 31.08 | |||||
| Price-to-Tangible-Book | 31.29 | |||||
| EV-to-EBIT | -70.95 | |||||
| EV-to-EBITDA | -71.7 | |||||
| EV-to-FCF | -116.43 | |||||
| Price-to-Net-Current-Asset-Value | 31.83 | |||||
| Price-to-Net-Cash | 32.39 | |||||
| Earnings Yield (Greenblatt) % | -1.41 | |||||
| FCF Yield % | -0.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Summit Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | |||
| EPS (TTM) (MXN) | -4.384 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 54.88 | ||
| 14-Day ATR (MXN) | 1.058557 | ||
| 20-Day SMA (MXN) | 377.534 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (MXN) | 374 - 430 | ||
| Shares Outstanding (Mil) | 737.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Summit Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Summit Therapeutics Inc Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Summit Therapeutics Inc Frequently Asked Questions
What is Summit Therapeutics Inc(MEX:SMMT)'s stock price today?
The current price of MEX:SMMT is MXN385.78. The 52 week high of MEX:SMMT is MXN430.00 and 52 week low is MXN374.00.
When is next earnings date of Summit Therapeutics Inc(MEX:SMMT)?
The next earnings date of Summit Therapeutics Inc(MEX:SMMT) is 2025-02-20 Est..
Does Summit Therapeutics Inc(MEX:SMMT) pay dividends? If so, how much?
Summit Therapeutics Inc(MEX:SMMT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers